drugset / Trial / NCT03428425
A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the efficacy and safety of HIPEC plus apatinib and S-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells
Timeline
- Start
- 2018-02
- Primary completion
- 2018-12
- Completion
- 2024-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 70 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | S-1 | Small molecule | 40 mg | — |
| Subject | S-1 | Small molecule | 50 mg | — |
| Subject | S-1 | Small molecule | 60 mg | — |